This issue provides an update on the OGTR office.
Details of OGTR monitoring and compliance activities during the quarter ended 31 December 2021
This Communiqué covers matters considered at the 30th videoconference of the Gene Technology Technical Advisory Committee (28 April 2022).
Details of OGTR monitoring and compliance activities during the quarter ended 31 March 2022.
Commercial supply of a genetically modified vaccine against infectious laryngotracheitis virus in chickens
Regulatory approvals for activities with GMOs include two licence types based on whether or not they involve an intentional release of the GMO into the environment. Here is an explanation of what this means.
This Communique covers matters considered at the 16th meeting of the Gene Technology Ethics and Community Consultative Committee (24 June 2022).
This application form is for licences to conduct human clinical trials of GMOs.
Human clinical trials of GM therapeutics may require either a DIR or DNIR licence. Find out how to apply for a licence to conduct a human clinical trial of a GMO.
Limited and controlled release of perennial ryegrass genetically modified for increased metabolisable energy content